BIOXCEL THERAPEUTICS INC. - COMMON STOCK

BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results

14 11 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

08 11 2023 06:00:02 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

06 11 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023

31 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services

30 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site

25 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer

10 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film

04 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization

14 8 2023 06:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023

31 7 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation

29 6 2023 05:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences

01 6 2023 06:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia

25 5 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) Program

16 5 2023 06:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights

08 5 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference

02 5 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023

24 4 2023 06:00:00 提供 Nasdaq GlobeNewswire

OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

14 3 2023 15:15:08 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

09 3 2023 06:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

23 2 2023 06:00:02 提供 Nasdaq GlobeNewswire